MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bcp.2014.11.014

Медицинская библиотека · Biochemical pharmacology · 2014

UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.

Dong Haiyan, Yang Xiang, Xie Jingjing, Xiang Liping, Li Yuanfang, Ou Minrui, Chi Ting, Liu Zhenhua, Yu Suhong, Gao Yu, Chen Jianzhong, Shao Jingwei, Jia Lee

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Targeting cancer cell glucose metabolism is a promising strategy for cancer therapy. In past approaches to cancer drug discovery, ursolic acid (UA) has been chemically modified to improve its antitumor activities and bioavailability. Here, a novel ursolic acid (UA) derivative UP12 was developed via computer-aided drug design to explore potent anti-cancer agents and to examine possible mechanisms. The structural docking analyses suggested that UP12 could bind to the active sites of glucokinase (GK), glucose transporter 1 (GLUT1) and ATPase, which are the main enzymes involved in cancer glucose metabolism. We further investigated the synergistic effect between UP12 and glycolysis inhibitor 2-deoxy-d-glucose (2-DG) in inhibiting glucose metabolism of cancer cells. The pharmacological results showed that the combination enhanced depletion of intracellular ATP and decrease in lactate production, and pushed more cancer cells arrested in the S and G2/M cycle phases. The combination selectively down-regulated the expression of Bcl-2 and HKII proteins, up-regulated the expression of Bax and p53, and collectively resulted in enhanced apoptosis related to caspase-3, -8, and -9 activities, in addition to inhibition on the cell mitochondrial membrane potential. The animal studies further demonstrated that the combination exhibited significant antitumor activity without obvious toxicity. In summary, UP12 can interfere cancer cell metabolism pathway and further enhance the therapeutic effects of 2-DG likely through synergistic suppression of cancer cell glucose metabolism, making UP12 a likely new candidate for anti-cancer drug development.

Для цитирования: Dong Haiyan, Yang Xiang, Xie Jingjing, Xiang Liping, Li Yuanfang, Ou Minrui, Chi Ting, Liu Zhenhua, Yu Suhong, Gao Yu, Chen Jianzhong, Shao Jingwei, Jia Lee. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.. Biochemical pharmacology. 2014. DOI: 10.1016/j.bcp.2014.11.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.